Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Calidi Biotherapeutics, Inc

< Previous 1 2 Next >
News headline image
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Provides Required NYSE American Disclosure
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Proposed Public Offering
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.